摘要
目的探讨沙库巴曲缬沙坦钠片对心力衰竭合并低钠血症患者心室重构的影响。方法选取2017年3月至2020年3月江苏省淮安市第一人民医院分院诊治的82例心力衰竭合并低钠血症患者,以随机数字表法分为研究组及对照组,每组各41例。对照组给予托伐普坦片,研究组给予托伐普坦片、沙库巴曲缬沙坦钠片。比较两组治疗效果及药物安全性。结果研究组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组左室射血分数(LVEF)高于治疗前,左室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)低于治疗前,差异有统计学意义(P<0.05);研究组治疗后LVEDD、LVESD低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血钠高于治疗前,N末端脑钠肽前体(NTpro-BNP)、白细胞介素-33(IL-33)低于治疗前,差异有统计学意义(P<0.05);研究组治疗后血钠含量高于对照组,NTpro-BNP、IL-33低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦钠片治疗心力衰竭合并低钠血症可抑制心室重构,改善低钠血症、炎症因子、神经内分泌因子水平,进而增强治疗疗效,且安全性良好。
Objective To investigate the effects of Sacubitril and Valsartan Sodium Tablets on ventricular remodeling in patients with heart failure complicated with hyponatremia.Methods A total of 82 patients with heart failure complicated with hyponatremia who were diagnosed and treated in Huai’an First People’s Hospital Branch from March 2017 to March 2020 were selected and divided into study group and control group by random number table method,with 41 cases in each group.The control group was given Tolvaptan Tablets,while the study group was given Tolvaptan Tablets,Sacubitril and Valsartan Sodium Tablets.The therapeutic effect and drug safety of the two groups were compared.Results The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,left ventricular ejection fraction(LVEF)in two groups was higher than before treatment,left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were lower than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the LVEDD and LVESD in the study group were lower than those in the control group,while the LVEF was higher than that in the control group,with statistically significant differences(P<0.05).After treatment,serum sodium in the two groups was higher than before treatment,and N-terminal brain natriuretic peptide precursor(NTpro-BNP)and interleukin-33(IL-33)were lower than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the sodium content in the study group was higher than that in the control group,while the levels of NTpro-BNP and IL-33 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril and Valsartan Sodium Tablets in the treatment of heart failure comp
作者
高刻
杨君
徐华建
GAO Ke;YANG Jun;XU Huajian(Department of Cardiovascular Internal Medicine,Huai’an First People’s Hospital Branch,Jiangsu Province,Huaian 223002,China)
出处
《中国医药导报》
CAS
2022年第11期77-80,共4页
China Medical Herald
基金
江苏高校哲学社会科学研究基金资助项目(2018SJA0300)。
关键词
沙库巴曲缬沙坦钠片
低钠血症
心力衰竭
心室重构
Sacubitril and Valsartan Sodium Tablets
Hyponatremia
Heart failure
Ventricular remodeling
